Dual Trigger to Reduce Ovarian Hyperstimulation Syndrome

Chenshiling

Status: Unknown

Conditions: Infertility and at High Risk of OHSS

Treatments: Drug: hCG; Drug: triptorelin

Study type: Interventional

Funder types: Other

Identifiers

NCT02022228

Dual Trigger

Details and patient eligibility

About

Gonadotropin releasing hormone (GnRH) agonist is sufficient for triggering final oocyte maturation in GnRH antagonist protocol and can significantly reduce incidence of ovarian hyperstimulation syndrome (OHSS) in high-risk patients.

However, lower oocyte yield was reported in patients with lower luteinizing hormone (LH) level post trigger with single injection of GnRH agonist, which might be related to the shorter duration and lower amount of LH induced by GnRH agonist.

Our aim is to study dual trigger with GnRH agonist and human chorionic gonadotropin (hCG) for preventing OHSS and maintaining clinical outcome in high risk patients who receive controlled ovarian stimulation in GnRH antagonist protocol.

Enrollment: 200 estimated patients

Sex: Female

Ages: Under 40 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patients with polycystic ovarian syndrome
• patients with polycystic ovarian morphology on ultrasound
• patients who previously experienced an ovarian stimulation cycle, with a high response to gonadotrophins

Exclusion criteria

• patients undergoing coasting
• patients with past ovarian surgery

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

200 participants in 2 patient groups

0.2mg triptorelin and 500 IU hCG

Experimental group

Description:

Patients were triggered with 0.2mg triptorelin and 500 IU hCG

Treatment:

Drug: hCG

Drug: hCG

Drug: triptorelin

0.2mg triptorelin and 1000 IU hCG

Experimental group

Description:

Patients were triggered with 0.2mg triptorelin and 1000 IU hCG

Treatment:

Drug: hCG

Drug: hCG

Drug: triptorelin